Last reviewed · How we verify
BDP HFA 100 µg pMDI
BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | BDP HFA 100 µg pMDI |
|---|---|
| Also known as | Qvar®, beclomethasone dipropionate hydrofluoralkane |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate is a topical corticosteroid delivered via pressurized metered-dose inhaler (pMDI) that suppresses inflammatory responses in the respiratory tract. It inhibits the release of inflammatory mediators and reduces mucus production, airway edema, and eosinophil infiltration. The HFA (hydrofluoroalkane) formulation provides improved lung deposition compared to older CFC propellants.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia / hoarseness
- Tremor
- Headache
- Palpitations
Key clinical trials
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects (PHASE2)
- Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI) (PHASE2)
- Foster With or Without Charcoal Block or Aerochamber Plus (PHASE1)
- A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma (PHASE3)
- Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma (PHASE3)
- Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDP HFA 100 µg pMDI CI brief — competitive landscape report
- BDP HFA 100 µg pMDI updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI